阴道二氧化碳激光治疗与标准药物治疗对绝经泌尿生殖综合征相关性交困难的成本效果分析
本研究采用决策树模型对阴道雌激素、口服奥培米芬和阴道二氧化碳激光三种治疗绝经泌尿生殖综合征相关性交困难的策略进行成本效果分析。结果显示三种策略在每质量调整生命年5万美元支付意愿阈值下均具成本效果,阴道二氧化碳激光的增量成本效果比为16372.01美元,奥培米芬为5711.14美元,激光治疗为最优策略。单因素敏感性分析显示激光治疗依从性低于38.8%时不再具成本效果。
要点
- 三种治疗在每QALY 5万美元阈值下均具成本效果,激光治疗为最优策略。
- 激光治疗依从性低于38.8%时不再具成本效果。
- 激光治疗成本降至当前20%时,依从性高于29%即为最优策略。
核心结论
- 阴道二氧化碳激光治疗对绝经泌尿生殖综合征相关性交困难具成本效果,阴道雌激素和口服奥培米芬亦然,激光治疗为最优成本效果策略;若FDA试验证实安全有效,应考虑保险覆盖。
研究设计与样本
- 经机构审查委员会豁免的成本效果分析,使用TreeAge Pro软件构建决策树,整合已发表文献的经验数据,并进行龙卷风图及单因素和双因素敏感性分析。
主要发现
- 三种治疗在每质量调整生命年50000美元支付意愿阈值下对中度性交困难均具成本效果。
- 阴道二氧化碳激光治疗的增量成本效果比为16372.01美元,奥培米芬治疗的增量成本效果比为5711.14美元。
- 尽管三种策略均位于有效前沿,阴道二氧化碳激光治疗为效果最高的最优治疗策略。
- 单因素敏感性分析中,激光治疗依从性降至38.8%以下时不再具成本效果,而阴道雌激素和奥培米芬在所有依从性范围内均保持成本效果。
- 依从性均为100%时,口服奥培米芬被激光和阴道雌激素 dominated;双因素分析中激光成本为当前200%(5554.00美元)且依从性>55%时仍为最优,成本降至当前20%(555.40美元)时依从性>29%即为最优。
临床怎么用
- 原文结论认为阴道二氧化碳激光治疗为最优成本效果策略,若FDA试验证实安全有效应考虑保险覆盖。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Topical vaginal estrogen therapy is considered the gold standard treatment for genitourinary syndrome of menopause-associated dyspareunia, but early investigations of energy-based devices show promise for patients with contraindications or those who are refractory to vaginal estrogen cream therapy. Although evaluating safety, efficacy, and long-term outcomes for novel technologies is critically important when new technologies become available to treat unmet healthcare needs, evaluation of the costs of these new technologies compared with existing therapies is also critically important but often understudied. OBJECTIVE: We sought to perform a cost-effectiveness analysis of 3 therapies for genitourinary syndrome of menopause, including vaginal estrogen therapy, oral ospemifene therapy, and vaginal CO2 laser therapy and determine if vaginal laser therapy is a cost-effective treatment strategy for dyspareunia associated with genitourinary syndrome of menopause. STUDY DESIGN: An institutional review board-exempt cost-effectiveness analysis was performed by constructing a decision tree using decision analysis software (TreeAge Pro; TreeAge Software, Inc, Williamstown, MA) using integrated empirical data from the published literature. Tornado plots and 1-way and 2-way sensitivity analyses were performed to assess how changes in the model's input parameters altered the overall outcome of the cost-effectiveness analysis model. RESULTS: All 3 treatment methods were found to be cost-effective below the willingness-to-pay threshold of $50,000.00 per quality-adjusted life year for moderate dyspareunia. The incremental cost-effectiveness ratio for vaginal CO2 laser therapy was $16,372.01 and the incremental cost-effectiveness ratio for ospemifene therapy was $5711.14. Although all 3 treatment strategies were on the efficient frontier, vaginal CO2 laser therapy was the optimal treatment strategy with the highest effectiveness. In a 1-way sensitivity analysis of treatment adherence, vaginal CO2 laser therapy was no longer cost-effective when the adherence fell below 38.8%. Vaginal estrogen cream and ospemifene therapies remained cost-effective treatment strategies at all ranges of adherence. When varying the adherence to 100% for all strategies, oral ospemifene therapy was "dominated" by both vaginal CO2 laser therapy and vaginal estrogen cream therapy. In a 2-way sensitivity analysis of vaginal CO2 laser therapy adherence and vaginal CO2 laser therapy cost, vaginal CO2 laser therapy still remained the optimal treatment strategy at 200% of its current cost ($5554.00) when the adherence was >55%. When the cost fell to 20% of its current cost ($555.40), it was the optimal treatment strategy at all adherence values above 29%. CONCLUSION: This study showed that vaginal fractional CO2 laser therapy is a cost-effective treatment strategy for dyspareunia associated with GSM, as are both vaginal estrogen and oral ospemifene therapies. In our model, vaginal CO2 laser therapy is the optimal cost-effective treatment strategy, and insurance coverage should be considered for this treatment option if it is proven to be safe and effective in FDA trials.
引用
- Wallace SL, St Martin B, Lee K, et al. A cost-effectiveness analysis of vaginal carbon dioxide laser therapy compared with standard medical therapies for genitourinary syndrome of menopause-associated dyspareunia. Am J Obstet Gynecol. 2020. PMID: 32562659. doi:10.1016/j.ajog.2020.06.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。